Biotech company Alterity Therapeutics is seeking to raise about $40 million following stellar results from a Phase 2 results study lasr week that sent its shares rocketing 50 per cent.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
This is where RNA-based therapies are poised to make a significant impact. RNA-based precision therapeutics are emerging as a game-changer for genetic disorders, including IRDs. Unlike DNA or ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...
Silexion Therapeutics Corp. announced the immediate exercise of outstanding warrants to purchase 2,221,523 ordinary shares at an exercise price of $1.35 per share, expected to yield approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results